Decreased expression of Annexin A1 correlates with pathologic differentiation grade in oral squamous cell carcinoma

Zhang, Lei; Yang, Xiao; Zhong, Lai‐ping; Zhou, Xin; Pan, Haiyang; Wei, Kui-Jie; Li, Jiang; Chen, Wantao; Zhang, Zhiyuan

doi:10.1111/j.1600-0714.2008.00678.x

Cited by 34 publications

(32 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zhu et al (24,25) and Zhang et al (26) reported that ANXA1 expression is significantly correlated with the pathological differentiation grade in OSCC patients. A lower ANXA1 expression in OSCC tissues correlates to a poorer pathologic differentiation grade (25,26). ANXA1 mRNA is downregulated in peripheral blood from OSCC patients compared with that in negative control individuals (18).…”

Section: Discussionmentioning

confidence: 99%

“…However, ANXA1 acts as a tumor suppressor by reducing cell proliferation and attenuating the metastatic potential in breast cancer (23). Certain clinical studies revealed that ANXA1 is downregulated in OSCC patients, and its expression is associated with the pathologic differentiation grade in OSCC patients (18,(24)(25)(26). However, the direct function of ANXA1 in OSCC progression has remained to be fully elucidated.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

ANXA1 affects cell proliferation, invasion and epithelial‑mesenchymal transition of oral squamous cell carcinoma

et al. 2017

View full text Add to dashboard Cite

Abstract. Annexin A1 (ANXA1) acts either as a tumor suppressor or an oncogene in different tumor types. Several clinical studies revealed that the expression of ANXA1 is associated with the pathologic differentiation grade in oral squamous cell carcinoma (OSCC) patients. However, the direct function of ANXA1 in OSCC progression has remained to be fully clarified. The present study was designed to investigate the role of ANXA1 in OSCC cell proliferation and invasion in vitro. Furthermore, whether ANXA1 was involved in transforming growth factor β1 (TGFβ1)/epidermal growth factor (EGF)-induced epithelial-mesenchymal transition (EMT) in OSCC was explored. Tca-8113 and SCC-9 cells were transfected with ANXA1-pcDNA3.1 plasmid to overexpress ANXA1. Subsequently, cell proliferation and invasion were examined using MTT and Transwell-Matrigel invasion assays. TGFβ1 and EGF were used to induce EMT in Tca-8113 and SCC-9 cells, and the expression of epithelial (E)-cadherin, neural (N)-cadherin and vimentin was determined by western blot analysis. The results demonstrated that ANXA1 overexpression induced a significant decrease of cell growth and invasiveness in Tca-8113 and SCC-9 cells. The expression of E-cadherin was significantly increased, while the expression of vimentin and N-cadherin was significantly decreased in ANXA1-overexpressing Tca-8113 and SCC-9 cells. ANXA1 expression was significantly decreased in TGFβ1/EGF-treated cells. Furthermore TGFβ1/EGF-induced EMT in OSCC cell lines was attenuated by ANXA1 overexpression. In conclusion, to the best of our knowledge, the present study was the first to evidence that ANXA1 inhibits OSCC cell proliferation and invasion in vitro. TGFβ1/EGF-induced EMT was reversed by ANXA1 in OSCC. ANXA1 was suggested to be a potential marker for OSCC as well as a novel treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

ANXA1 affects cell proliferation, invasion and epithelial‑mesenchymal transition of oral squamous cell carcinoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The upregulation of ANXA1 has been cor related with the development of hepatocellular carcinoma, colorectal cancer, lung cancer, pancreatic cancer, melanoma, skin cancer and endometrial carcinoma (21)(22)(23)(24)(25)(26)(27). Furthermore, its downregulation, as well as the translocation of ANXA1, has been shown to be a positive indicator for the development, progression and metastasis of prostate cancer, esophageal cancer, oral carcinoma, cervical cancer, intestinal-type sinonasal adenocarcinoma and NPC (17)(18)(19)28,29). Yu et al (20) reported that the expression of ANXA1 was downregulated in the adriamycin-resistant cell line (pumc-91/ADM) compared with its parental cell line (pumc-91).…”

Section: Discussionmentioning

confidence: 99%

“…In recent years, the role of ANXA1 in the malignant tumor has emerged as a research focus in oncology. Accumulating evidence has indicated that ANXA1 dysregulation is associated with the occurrence, development, invasion, metastasis and drug resistance of cancers (17)(18)(19)(20). The research evidence indicated that ANXA1 may specifically function as either a tumor suppressor or an oncogene candidate for certain cancers depending on the particular type of tumor cells/tissues (9).…”

Section: Discussionmentioning

confidence: 99%

Downregulation of Annexin A1 is correlated with radioresistance in nasopharyngeal carcinoma

Huang

Liao

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

“…Oral squamous cell carcinoma (OSCC), the sixth most common cancer, continues to be the most prevalent cancer related to the consumption of tobacco and alcohol [1], affecting approximately 500,000 patients worldwide each year [2,3]. More than 300,000 new cases are reported in America every year, and approximately 9,000 patients die each year of the disease.…”

Section: Introductionmentioning

confidence: 99%

High Efficacy in Hyperthermia-associated with Polyphosphate Magnetic Nanoparticles for Oral Cancer Treatment

Taboga¹

2014

J Nanomed Nanotechnol

View full text Add to dashboard Cite

Nanotherapy applied to cancer treatment is constantly evolving, and new approaches to current techniques, such as magnetohyperthermia, are being implemented to solve and minimize the limitations of conventional therapeutic strategies. The purpose of this study was to investigate the action of polyphosphate-coated maghemite nanoparticles (MNPs) on oral squamous cell carcinoma. Human oral cancer cells (UM-SCC14A) were incubated with MNPs at various concentrations and subjected to cell proliferation tests (MTT), apoptosis assays and transmission electron image analysis. Viability and apoptotic events were time and dose dependent. These in vitro tests showed that at the intermediate concentration tested there is no significant toxicity, as confirmed by transmission electron microscopy. For this reason this MNPs concentration was chosen for the subsequent in vivo tests. Oral tumor induction was performed by applying the carcinogen DMBA to Syrian hamsters. Animals were then treated by magnetohyperthermia using MNPs. No signs of general clinical symptoms of toxicity or abnormal behavioral reactions were observed. However, animals treated with MNPs and exposed to the alternating magnetic field in the hyperthermia procedure exhibited a significant and time dependent cancer regression, as confirmed by histopathological analyses and immunohistochemistry. Actually, in quantitative terms of the magnetotherapy efficacy involving these polyphosphate-coated MNPs, 100% recovery (12/12) was observed in the oral cancer tumor bearing Syrian hamsters seven days after the treatment with the magnetohyperthermia procedure. Data supports the suggestion that the MNPs-mediated hyperthermia represents a promising strategy for the treatment of oral cancer.in patients with malignancies in the mouth region. Unlike many other oncology subspecialties, however, the rates of recurrence and overall survival have improved only modestly over the past decades, despite the continuous search for new therapeutic techniques [6,7]. Thus, it is expected that the identification and use of specific agents will lead to individualized treatments, which in turn will lead to significantly better results as manifested by more cures and better quality of life by decreasing toxicity [8].Over the last years, maghemite nanoparticles (MNPs) have appeared as a well-established technology and an important field of research in superparamagnetism of colloidal materials, characteristic which allows them to be guided with an external magnetic field [9]. Recently, MNPs have been investigated for therapeutic purposes such as hyperthermic treatment [10,11]. Magnetohyperthermia (MHT) represents a novel and promising therapy for cancer treatment [11,12], being capable of promoting the specific lysis of tumor cells, thereby improving patient outcomes while minimizing the subsequent toxicity effects [13]. The Citation: Candido NM, Calmon MF, Taboga SR, Bonilha JL, dos Santos MC, et al. (2014) High Efficacy in Hyperthermia-associated with Polyphosphate

show abstract

Decreased expression of Annexin A1 correlates with pathologic differentiation grade in oral squamous cell carcinoma

Cited by 34 publications

References 61 publications

ANXA1 affects cell proliferation, invasion and epithelial‑mesenchymal transition of oral squamous cell carcinoma

ANXA1 affects cell proliferation, invasion and epithelial‑mesenchymal transition of oral squamous cell carcinoma

Downregulation of Annexin A1 is correlated with radioresistance in nasopharyngeal carcinoma

High Efficacy in Hyperthermia-associated with Polyphosphate Magnetic Nanoparticles for Oral Cancer Treatment

Contact Info

Product

Resources

About